Mereo BioPharma Group plc (MREO) 10-Year Financial Performance & Capital Metrics

MREO • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutMereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.Show more

Revenue $0 -100.0%
EBITDA -$46M -69.2%
Net Income -$43M -46.8%
EPS (Diluted) -0.29 +100.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -77.58% -34.2%
ROIC -
Debt/Equity 0.11 -10.5%
Interest Coverage -34.56 -250.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 1 (bottom 1%)
✗Shares diluted 12.2% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-50%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM8.4%

EPS CAGR

10Y-

5Y-

3Y-

TTM99.97%

ROCE

10Y Avg-55.51%

5Y Avg-54.4%

3Y Avg-60.91%

Latest-79.23%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	-3.29M	0	0	0	49.21M	0	10M	0
Revenue Growth %	-	-	1%	-	-	-	-1%	-	-1%
Cost of Goods Sold+	24.56M	34.61M	22.7M	2.01M	2.05M	24.17M	-257.44K	2.57M	0
COGS % of Revenue	-	-10.53%	-	-	-	0.49%	-	0.26%	-
Gross Profit+	-24.56M	-37.89M	-22.7M	-2.01M	-2.05M	25.04M	257.44K	7.43M	0
Gross Margin %	-	11.53%	-	-	-	0.51%	-	0.74%	-
Gross Profit Growth %	-	-0.54%	0.4%	0.91%	-0.02%	13.21%	-0.99%	27.85%	-1%
Operating Expenses+	11.62M	10.7M	12.5M	48.4M	46.13M	53.3M	53.92M	35.84M	47.36M
OpEx % of Revenue	-	-3.26%	-	-	-	1.08%	-	3.58%	-
Selling, General & Admin	11.62M	10.7M	12.5M	18.28M	25.16M	21.5M	23.18M	18.42M	26.43M
SG&A % of Revenue	-	-3.26%	-	-	-	0.44%	-	1.84%	-
Research & Development	24.56M	34.61M	22.7M	30.12M	20.96M	31.8M	30.75M	17.42M	20.93M
R&D % of Revenue	-	-10.53%	-	-	-	0.65%	-	1.74%	-
Other Operating Expenses	0	-293.33K	0	0	0	0	0	0	0
Operating Income+	-36.18M	-45.3M	-35.21M	-50.41M	-48.18M	-28.26M	-53.67M	-28.42M	-47.36M
Operating Margin %	-	13.79%	-	-	-	-0.57%	-	-2.84%	-
Operating Income Growth %	-	-0.25%	0.22%	-0.43%	0.04%	0.41%	-0.9%	0.47%	-0.67%
EBITDA+	-36.15M	-45.27M	-35.17M	-48.4M	-46.13M	-27.39M	-52.77M	-27.36M	-46.28M
EBITDA Margin %	-	13.78%	-	-	-	-0.56%	-	-2.74%	-
EBITDA Growth %	-	-0.25%	0.22%	-0.38%	0.05%	0.41%	-0.93%	0.48%	-0.69%
D&A (Non-Cash Add-back)	32.94K	36.08K	37.8K	2.01M	2.05M	866.47K	895.5K	1.06M	1.09M
EBIT	-33.74M	-45.6M	-32.89M	-46.58M	-205.46M	24.62M	-40.87M	-27.12M	-41.88M
Net Interest Income+	15.38K	-263.07K	-2.05M	-3.12M	-6.34M	-5.22M	-2.67M	-750K	1.67M
Interest Income	195.14K	826.86K	306.83K	377K	44K	1.38K	696K	2.13M	3.04M
Interest Expense	179.76K	1.09M	2.36M	3.5M	6.38M	5.22M	3.36M	2.88M	1.37M
Other Income/Expense	2.46M	-1.65M	-2.1M	-2.04M	-165.27M	47.48M	9.21M	-1.58M	4.11M
Pretax Income+	-33.72M	-46.95M	-37.31M	-52.46M	-213.45M	19.22M	-44.46M	-30M	-43.25M
Pretax Margin %	-	14.29%	-	-	-	0.39%	-	-3%	-
Income Tax+	-5.33M	-8.15M	-5.28M	-8M	-3.62M	2.05M	-2.34M	-532K	0
Effective Tax Rate %	0.84%	0.83%	0.86%	0.85%	0.98%	0.89%	0.95%	0.98%	1%
Net Income+	-28.39M	-38.8M	-32.03M	-44.45M	-209.83M	17.17M	-42.12M	-29.47M	-43.25M
Net Margin %	-	11.81%	-	-	-	0.35%	-	-2.95%	-
Net Income Growth %	-	-0.37%	0.17%	-0.39%	-3.72%	1.08%	-3.45%	0.3%	-0.47%
Net Income (Continuing)	-28.39M	-38.8M	-32.03M	-44.45M	-209.83M	17.17M	-42.12M	-29.47M	-43.25M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-19553.91	-19003.80	-14352.87	-12902.58	-16503.30	749.65	-1750.35	-1100.22	-0.29
EPS Growth %	-	0.03%	0.24%	0.1%	-0.28%	1.05%	-3.33%	0.37%	1%
EPS (Basic)	-19553.91	-19003.80	-14352.87	-12902.58	-16503.30	749.65	-1750.35	-1100.22	-0.29
Diluted Shares Outstanding	8.96M	13.8M	14.23M	17.88M	67.79M	116.73M	120.64M	131.89M	147.92M
Basic Shares Outstanding	8.96M	13.8M	14.23M	17.87M	67.79M	116.73M	120.64M	131.89M	147.92M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	60.78M	63.18M	34.5M	40.32M	40.65M	134.32M	75.2M	63.76M	74.76M
Cash & Short-Term Investments	53.58M	52.54M	27.54M	21.65M	32.09M	127.52M	68.18M	57.42M	69.8M
Cash Only	53.58M	50.04M	25.04M	20.93M	31.35M	126.75M	68.18M	57.42M	69.8M
Short-Term Investments	0	2.5M	2.5M	720.63K	748.03K	769.47K	0	0	0
Accounts Receivable	995.78K	509.35K	0	0	0	0	0	3.73M	3.25M
Days Sales Outstanding	-	-56.59	-	-	-	-	-	136.22	-
Inventory	-53.92M	-2.5M	-293.33K	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	5.1M	8.15M	5.89M	15.87M	6.34M	3.01M	3.23M	1.98M	507K
Total Non-Current Assets+	25.99M	33.16M	32.78M	74.2M	45.43M	36.64M	2.22M	2.74M	1.63M
Property, Plant & Equipment	173.87K	153.36K	148.94K	15.31M	2.15M	3.42M	2.22M	1.65M	984K
Fixed Asset Turnover	-	-21.42x	-	-	-	14.38x	-	6.06x	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	25.81M	33.01M	32.63M	58.89M	43.28M	33.22M	0	1.09M	643K
Long-Term Investments	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	1	0	1	0	0	0
Total Assets+	86.76M	96.34M	67.28M	114.52M	86.08M	170.96M	77.41M	66.5M	76.39M
Asset Turnover	-	-0.03x	-	-	-	0.29x	-	0.15x	-
Asset Growth %	-	0.11%	-0.3%	0.7%	-0.25%	0.99%	-0.55%	-0.14%	0.15%
Total Current Liabilities+	3.21M	9.62M	16.18M	39.58M	11.71M	16.96M	24.38M	9.49M	13.85M
Accounts Payable	1.23M	2.64M	5.57M	8.14M	4.33M	3.09M	3.49M	2.35M	2.44M
Days Payables Outstanding	18.24	27.83	89.62	1.48K	770.45	46.67	-4.95K	332.67	-
Short-Term Debt	0	1.94M	6.84M	20.05M	0	0	13.33M	0	5.54M
Deferred Revenue (Current)	0	-163.72K	-177.71K	0	0	0	0	0	0
Other Current Liabilities	-750.31K	3.67M	-2.09M	906.09K	601.71K	7.6M	1.35M	2.37M	-413K
Current Ratio	18.94x	6.57x	2.13x	1.02x	3.47x	7.92x	3.09x	6.72x	5.40x
Quick Ratio	35.74x	6.83x	2.15x	1.02x	3.47x	7.92x	3.09x	6.72x	5.40x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	4.3M	24.23M	18.33M	21.61M	94.84M	34.99M	1.64M	6.48M	1.57M
Long-Term Debt	3.13M	18.81M	14.65M	7.12M	22.07M	19.45M	0	4.39M	0
Capital Lease Obligations	0	0	0	12.34M	1.58M	2.37M	1.48M	906K	187K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.17M	5.42M	3.68M	2.15M	71.18M	13.17M	157K	1.18M	1.39M
Total Liabilities	7.51M	33.85M	34.51M	61.19M	106.55M	51.95M	26.01M	15.96M	15.42M
Total Debt+	3.13M	20.75M	21.48M	42.94M	24.53M	22.66M	15.37M	5.95M	6.43M
Net Debt	-50.45M	-29.29M	-3.56M	22.01M	-6.82M	-104.08M	-52.81M	-51.47M	-63.37M
Debt / Equity	0.04x	0.33x	0.66x	0.81x	-	0.19x	0.30x	0.12x	0.11x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-201.26x	-41.57x	-14.91x	-14.42x	-7.55x	-5.41x	-15.97x	-9.86x	-34.56x
Total Equity+	79.26M	62.48M	32.77M	53.33M	-20.47M	119.01M	51.4M	50.54M	60.97M
Equity Growth %	-	-0.21%	-0.48%	0.63%	-1.38%	6.81%	-0.57%	-0.02%	0.21%
Book Value per Share	8.85	4.53	2.30	2.98	-0.30	1.02	0.43	0.38	0.41
Total Shareholders' Equity	79.26M	62.48M	32.77M	53.33M	-20.47M	119.01M	51.4M	50.54M	60.97M
Common Stock	193.02K	213.28K	213.72K	389.46K	1.39M	2.37M	2.48M	2.77M	3.06M
Retained Earnings	-33.58M	-79.32M	-111.22M	-193.49M	-423.51M	-401.6M	-404.57M	-419.63M	-462.88M
Treasury Stock	0	0	-389.55K	0	0	0	-1.33M	-1.23M	0
Accumulated OCI	12.67M	23.36M	25.59M	85.23M	180.4M	183.58M	-21.69M	-17.48M	-18.85M
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-27.4M	-32.15M	-23.14M	-60.22M	-38.62M	-7.07M	-48.82M	-21.13M	-32.83M
Operating CF Margin %	-	9.79%	-	-	-	-0.14%	-	-2.11%	-
Operating CF Growth %	-	-0.17%	0.28%	-1.6%	0.36%	0.82%	-5.9%	0.57%	-0.55%
Net Income	-33.72M	-46.95M	-37.31M	-53.91M	-226.84M	19.22M	-42.22M	-29.47M	-43.25M
Depreciation & Amortization	32.94K	36.08K	37.8K	2.07M	2.18M	866.47K	889K	1.06M	1.09M
Stock-Based Compensation	6.49M	3.65M	2.19M	2.15M	2.12M	4.46M	4.77M	4.92M	7.39M
Deferred Taxes	1.6M	7.34M	7.62M	0	0	0	0	0	0
Other Non-Cash Items	179.76K	751.65K	1.92M	-472.02K	188.56M	-29.12M	-9.91M	3.94M	2.31M
Working Capital Changes	-1.99M	3.02M	2.41M	-10.05M	-4.65M	-2.49M	-2.35M	-1.59M	-369K
Change in Receivables	0	0	0	-1.23M	192.16K	-794.94K	-3.47M	456K	-1.65M
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	617K	-1.26M	146K
Cash from Investing+	372.61K	-3.74M	251.56K	56.77M	2.04M	-568.2K	1.99M	-419K	-699K
Capital Expenditures	-3.47K	-2.3M	-35.54K	-27.53K	-21.8K	-722.06K	-13K	0	-699K
CapEx % of Revenue	-	-0.7%	-	-	-	0.01%	-	0.04%	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	376.08K	1.05M	287.09K	494.31K	2.54M	153.86K	2M	-419K	0
Cash from Financing+	68.36M	33.74M	-2.07M	-7.49M	47.34M	104.8M	200K	7.97M	46.15M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	-3.7M	-1.7M	-2.61M	-3.28M	-10.75M	-253.73K	200K	24K	-853K
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-27.4M	-34.44M	-23.17M	-60.25M	-38.65M	-7.79M	-48.83M	-21.55M	-33.53M
FCF Margin %	-	10.48%	-	-	-	-0.16%	-	-2.16%	-
FCF Growth %	-	-0.26%	0.33%	-1.6%	0.36%	0.8%	-5.27%	0.56%	-0.56%
FCF per Share	-3.06	-2.50	-1.63	-3.37	-0.57	-0.07	-0.40	-0.16	-0.23
FCF Conversion (FCF/Net Income)	0.97x	0.83x	0.72x	1.35x	0.18x	-0.41x	1.16x	0.72x	0.76x
Interest Paid	0	0	0	0	0	0	0	0	21K
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-35.82%	-54.75%	-67.25%	-103.26%	-1277.35%	34.86%	-49.44%	-57.81%	-77.58%
Return on Invested Capital (ROIC)	-94.2%	-109.61%	-84.63%	-72.33%	-150.42%	-142.01%	-595.78%	-	-
Gross Margin	-	1153.38%	-	-	-	50.89%	-	74.26%	-
Net Margin	-	1180.99%	-	-	-	34.9%	-	-294.66%	-
Debt / Equity	0.04x	0.33x	0.66x	0.81x	-	0.19x	0.30x	0.12x	0.11x
Interest Coverage	-201.26x	-41.57x	-14.91x	-14.42x	-7.55x	-5.41x	-15.97x	-9.86x	-34.56x
FCF Conversion	0.97x	0.83x	0.72x	1.35x	0.18x	-0.41x	1.16x	0.72x	0.76x
Revenue Growth	-	-	100%	-	-	-	-100%	-	-100%

Frequently Asked Questions

Growth & Financials

Mereo BioPharma Group plc (MREO) reported $0.5M in revenue for fiscal year 2024.

Mereo BioPharma Group plc (MREO) saw revenue decline by 100.0% over the past year.

Mereo BioPharma Group plc (MREO) reported a net loss of $41.5M for fiscal year 2024.

Dividend & Returns

Mereo BioPharma Group plc (MREO) has a return on equity (ROE) of -77.6%. Negative ROE indicates the company is unprofitable.

Mereo BioPharma Group plc (MREO) had negative free cash flow of $33.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Mereo BioPharma Group plc (MREO) 10-Year Financial Performance & Capital Metrics

MREO • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $0 -100.0%
EBITDA -$46M -69.2%
Net Income -$43M -46.8%
EPS (Diluted) -0.29 +100.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -77.58% -34.2%
ROIC -
Debt/Equity 0.11 -10.5%
Interest Coverage -34.56 -250.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 1 (bottom 1%)
✗Shares diluted 12.2% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-50%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM8.4%

EPS CAGR

10Y-

5Y-

3Y-

TTM99.97%

ROCE

10Y Avg-55.51%

5Y Avg-54.4%

3Y Avg-60.91%

Latest-79.23%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	-3.29M	0	0	0	49.21M	0	10M	0
Revenue Growth %	-	-	1%	-	-	-	-1%	-	-1%
Cost of Goods Sold+	24.56M	34.61M	22.7M	2.01M	2.05M	24.17M	-257.44K	2.57M	0
COGS % of Revenue	-	-10.53%	-	-	-	0.49%	-	0.26%	-
Gross Profit+	-24.56M	-37.89M	-22.7M	-2.01M	-2.05M	25.04M	257.44K	7.43M	0
Gross Margin %	-	11.53%	-	-	-	0.51%	-	0.74%	-
Gross Profit Growth %	-	-0.54%	0.4%	0.91%	-0.02%	13.21%	-0.99%	27.85%	-1%
Operating Expenses+	11.62M	10.7M	12.5M	48.4M	46.13M	53.3M	53.92M	35.84M	47.36M
OpEx % of Revenue	-	-3.26%	-	-	-	1.08%	-	3.58%	-
Selling, General & Admin	11.62M	10.7M	12.5M	18.28M	25.16M	21.5M	23.18M	18.42M	26.43M
SG&A % of Revenue	-	-3.26%	-	-	-	0.44%	-	1.84%	-
Research & Development	24.56M	34.61M	22.7M	30.12M	20.96M	31.8M	30.75M	17.42M	20.93M
R&D % of Revenue	-	-10.53%	-	-	-	0.65%	-	1.74%	-
Other Operating Expenses	0	-293.33K	0	0	0	0	0	0	0
Operating Income+	-36.18M	-45.3M	-35.21M	-50.41M	-48.18M	-28.26M	-53.67M	-28.42M	-47.36M
Operating Margin %	-	13.79%	-	-	-	-0.57%	-	-2.84%	-
Operating Income Growth %	-	-0.25%	0.22%	-0.43%	0.04%	0.41%	-0.9%	0.47%	-0.67%
EBITDA+	-36.15M	-45.27M	-35.17M	-48.4M	-46.13M	-27.39M	-52.77M	-27.36M	-46.28M
EBITDA Margin %	-	13.78%	-	-	-	-0.56%	-	-2.74%	-
EBITDA Growth %	-	-0.25%	0.22%	-0.38%	0.05%	0.41%	-0.93%	0.48%	-0.69%
D&A (Non-Cash Add-back)	32.94K	36.08K	37.8K	2.01M	2.05M	866.47K	895.5K	1.06M	1.09M
EBIT	-33.74M	-45.6M	-32.89M	-46.58M	-205.46M	24.62M	-40.87M	-27.12M	-41.88M
Net Interest Income+	15.38K	-263.07K	-2.05M	-3.12M	-6.34M	-5.22M	-2.67M	-750K	1.67M
Interest Income	195.14K	826.86K	306.83K	377K	44K	1.38K	696K	2.13M	3.04M
Interest Expense	179.76K	1.09M	2.36M	3.5M	6.38M	5.22M	3.36M	2.88M	1.37M
Other Income/Expense	2.46M	-1.65M	-2.1M	-2.04M	-165.27M	47.48M	9.21M	-1.58M	4.11M
Pretax Income+	-33.72M	-46.95M	-37.31M	-52.46M	-213.45M	19.22M	-44.46M	-30M	-43.25M
Pretax Margin %	-	14.29%	-	-	-	0.39%	-	-3%	-
Income Tax+	-5.33M	-8.15M	-5.28M	-8M	-3.62M	2.05M	-2.34M	-532K	0
Effective Tax Rate %	0.84%	0.83%	0.86%	0.85%	0.98%	0.89%	0.95%	0.98%	1%
Net Income+	-28.39M	-38.8M	-32.03M	-44.45M	-209.83M	17.17M	-42.12M	-29.47M	-43.25M
Net Margin %	-	11.81%	-	-	-	0.35%	-	-2.95%	-
Net Income Growth %	-	-0.37%	0.17%	-0.39%	-3.72%	1.08%	-3.45%	0.3%	-0.47%
Net Income (Continuing)	-28.39M	-38.8M	-32.03M	-44.45M	-209.83M	17.17M	-42.12M	-29.47M	-43.25M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-19553.91	-19003.80	-14352.87	-12902.58	-16503.30	749.65	-1750.35	-1100.22	-0.29
EPS Growth %	-	0.03%	0.24%	0.1%	-0.28%	1.05%	-3.33%	0.37%	1%
EPS (Basic)	-19553.91	-19003.80	-14352.87	-12902.58	-16503.30	749.65	-1750.35	-1100.22	-0.29
Diluted Shares Outstanding	8.96M	13.8M	14.23M	17.88M	67.79M	116.73M	120.64M	131.89M	147.92M
Basic Shares Outstanding	8.96M	13.8M	14.23M	17.87M	67.79M	116.73M	120.64M	131.89M	147.92M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	60.78M	63.18M	34.5M	40.32M	40.65M	134.32M	75.2M	63.76M	74.76M
Cash & Short-Term Investments	53.58M	52.54M	27.54M	21.65M	32.09M	127.52M	68.18M	57.42M	69.8M
Cash Only	53.58M	50.04M	25.04M	20.93M	31.35M	126.75M	68.18M	57.42M	69.8M
Short-Term Investments	0	2.5M	2.5M	720.63K	748.03K	769.47K	0	0	0
Accounts Receivable	995.78K	509.35K	0	0	0	0	0	3.73M	3.25M
Days Sales Outstanding	-	-56.59	-	-	-	-	-	136.22	-
Inventory	-53.92M	-2.5M	-293.33K	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	5.1M	8.15M	5.89M	15.87M	6.34M	3.01M	3.23M	1.98M	507K
Total Non-Current Assets+	25.99M	33.16M	32.78M	74.2M	45.43M	36.64M	2.22M	2.74M	1.63M
Property, Plant & Equipment	173.87K	153.36K	148.94K	15.31M	2.15M	3.42M	2.22M	1.65M	984K
Fixed Asset Turnover	-	-21.42x	-	-	-	14.38x	-	6.06x	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	25.81M	33.01M	32.63M	58.89M	43.28M	33.22M	0	1.09M	643K
Long-Term Investments	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	1	0	1	0	0	0
Total Assets+	86.76M	96.34M	67.28M	114.52M	86.08M	170.96M	77.41M	66.5M	76.39M
Asset Turnover	-	-0.03x	-	-	-	0.29x	-	0.15x	-
Asset Growth %	-	0.11%	-0.3%	0.7%	-0.25%	0.99%	-0.55%	-0.14%	0.15%
Total Current Liabilities+	3.21M	9.62M	16.18M	39.58M	11.71M	16.96M	24.38M	9.49M	13.85M
Accounts Payable	1.23M	2.64M	5.57M	8.14M	4.33M	3.09M	3.49M	2.35M	2.44M
Days Payables Outstanding	18.24	27.83	89.62	1.48K	770.45	46.67	-4.95K	332.67	-
Short-Term Debt	0	1.94M	6.84M	20.05M	0	0	13.33M	0	5.54M
Deferred Revenue (Current)	0	-163.72K	-177.71K	0	0	0	0	0	0
Other Current Liabilities	-750.31K	3.67M	-2.09M	906.09K	601.71K	7.6M	1.35M	2.37M	-413K
Current Ratio	18.94x	6.57x	2.13x	1.02x	3.47x	7.92x	3.09x	6.72x	5.40x
Quick Ratio	35.74x	6.83x	2.15x	1.02x	3.47x	7.92x	3.09x	6.72x	5.40x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	4.3M	24.23M	18.33M	21.61M	94.84M	34.99M	1.64M	6.48M	1.57M
Long-Term Debt	3.13M	18.81M	14.65M	7.12M	22.07M	19.45M	0	4.39M	0
Capital Lease Obligations	0	0	0	12.34M	1.58M	2.37M	1.48M	906K	187K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.17M	5.42M	3.68M	2.15M	71.18M	13.17M	157K	1.18M	1.39M
Total Liabilities	7.51M	33.85M	34.51M	61.19M	106.55M	51.95M	26.01M	15.96M	15.42M
Total Debt+	3.13M	20.75M	21.48M	42.94M	24.53M	22.66M	15.37M	5.95M	6.43M
Net Debt	-50.45M	-29.29M	-3.56M	22.01M	-6.82M	-104.08M	-52.81M	-51.47M	-63.37M
Debt / Equity	0.04x	0.33x	0.66x	0.81x	-	0.19x	0.30x	0.12x	0.11x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-201.26x	-41.57x	-14.91x	-14.42x	-7.55x	-5.41x	-15.97x	-9.86x	-34.56x
Total Equity+	79.26M	62.48M	32.77M	53.33M	-20.47M	119.01M	51.4M	50.54M	60.97M
Equity Growth %	-	-0.21%	-0.48%	0.63%	-1.38%	6.81%	-0.57%	-0.02%	0.21%
Book Value per Share	8.85	4.53	2.30	2.98	-0.30	1.02	0.43	0.38	0.41
Total Shareholders' Equity	79.26M	62.48M	32.77M	53.33M	-20.47M	119.01M	51.4M	50.54M	60.97M
Common Stock	193.02K	213.28K	213.72K	389.46K	1.39M	2.37M	2.48M	2.77M	3.06M
Retained Earnings	-33.58M	-79.32M	-111.22M	-193.49M	-423.51M	-401.6M	-404.57M	-419.63M	-462.88M
Treasury Stock	0	0	-389.55K	0	0	0	-1.33M	-1.23M	0
Accumulated OCI	12.67M	23.36M	25.59M	85.23M	180.4M	183.58M	-21.69M	-17.48M	-18.85M
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-27.4M	-32.15M	-23.14M	-60.22M	-38.62M	-7.07M	-48.82M	-21.13M	-32.83M
Operating CF Margin %	-	9.79%	-	-	-	-0.14%	-	-2.11%	-
Operating CF Growth %	-	-0.17%	0.28%	-1.6%	0.36%	0.82%	-5.9%	0.57%	-0.55%
Net Income	-33.72M	-46.95M	-37.31M	-53.91M	-226.84M	19.22M	-42.22M	-29.47M	-43.25M
Depreciation & Amortization	32.94K	36.08K	37.8K	2.07M	2.18M	866.47K	889K	1.06M	1.09M
Stock-Based Compensation	6.49M	3.65M	2.19M	2.15M	2.12M	4.46M	4.77M	4.92M	7.39M
Deferred Taxes	1.6M	7.34M	7.62M	0	0	0	0	0	0
Other Non-Cash Items	179.76K	751.65K	1.92M	-472.02K	188.56M	-29.12M	-9.91M	3.94M	2.31M
Working Capital Changes	-1.99M	3.02M	2.41M	-10.05M	-4.65M	-2.49M	-2.35M	-1.59M	-369K
Change in Receivables	0	0	0	-1.23M	192.16K	-794.94K	-3.47M	456K	-1.65M
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	617K	-1.26M	146K
Cash from Investing+	372.61K	-3.74M	251.56K	56.77M	2.04M	-568.2K	1.99M	-419K	-699K
Capital Expenditures	-3.47K	-2.3M	-35.54K	-27.53K	-21.8K	-722.06K	-13K	0	-699K
CapEx % of Revenue	-	-0.7%	-	-	-	0.01%	-	0.04%	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	376.08K	1.05M	287.09K	494.31K	2.54M	153.86K	2M	-419K	0
Cash from Financing+	68.36M	33.74M	-2.07M	-7.49M	47.34M	104.8M	200K	7.97M	46.15M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	-3.7M	-1.7M	-2.61M	-3.28M	-10.75M	-253.73K	200K	24K	-853K
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-27.4M	-34.44M	-23.17M	-60.25M	-38.65M	-7.79M	-48.83M	-21.55M	-33.53M
FCF Margin %	-	10.48%	-	-	-	-0.16%	-	-2.16%	-
FCF Growth %	-	-0.26%	0.33%	-1.6%	0.36%	0.8%	-5.27%	0.56%	-0.56%
FCF per Share	-3.06	-2.50	-1.63	-3.37	-0.57	-0.07	-0.40	-0.16	-0.23
FCF Conversion (FCF/Net Income)	0.97x	0.83x	0.72x	1.35x	0.18x	-0.41x	1.16x	0.72x	0.76x
Interest Paid	0	0	0	0	0	0	0	0	21K
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-35.82%	-54.75%	-67.25%	-103.26%	-1277.35%	34.86%	-49.44%	-57.81%	-77.58%
Return on Invested Capital (ROIC)	-94.2%	-109.61%	-84.63%	-72.33%	-150.42%	-142.01%	-595.78%	-	-
Gross Margin	-	1153.38%	-	-	-	50.89%	-	74.26%	-
Net Margin	-	1180.99%	-	-	-	34.9%	-	-294.66%	-
Debt / Equity	0.04x	0.33x	0.66x	0.81x	-	0.19x	0.30x	0.12x	0.11x
Interest Coverage	-201.26x	-41.57x	-14.91x	-14.42x	-7.55x	-5.41x	-15.97x	-9.86x	-34.56x
FCF Conversion	0.97x	0.83x	0.72x	1.35x	0.18x	-0.41x	1.16x	0.72x	0.76x
Revenue Growth	-	-	100%	-	-	-	-100%	-	-100%

Frequently Asked Questions

Growth & Financials

Mereo BioPharma Group plc (MREO) reported $0.5M in revenue for fiscal year 2024.

Mereo BioPharma Group plc (MREO) saw revenue decline by 100.0% over the past year.

Mereo BioPharma Group plc (MREO) reported a net loss of $41.5M for fiscal year 2024.

Dividend & Returns

Mereo BioPharma Group plc (MREO) has a return on equity (ROE) of -77.6%. Negative ROE indicates the company is unprofitable.

Mereo BioPharma Group plc (MREO) had negative free cash flow of $33.0M in fiscal year 2024, likely due to heavy capital investments.